Halle (Saale), 23.05.2022. Antimicrobial resistance continues to be on the rise despite increased public awareness. According to a study published in The Lancet, resistant germs were directly…

Halle (Saale), 23.11.2021. PerioTrap has received the official statement of its first Scientific Advisory Board Meeting which was held on October 19th at the company’s offices. The board consists of…

Halle (Saale), 16.08.2021. Infectious diseases are often treated with broadband antibiotics that act against a great range of bacteria. The systemic application of antibiotics always has a negative…

PerioTrap has published its efficient targeted periodontitis strategy that could minimize side effects and the overuse of broad-spectrum antibiotics.

PerioTrap has published its efficient targeted periodontitis strategy that could minimize side effects and the overuse of broad-spectrum antibiotics. It was developed and tested together with…


Team

PerioTrap Pharmaceuticals raises €3M seed round to develop selective anti-infectives to tackle periodontitis

Halle (Saale), 21.10.2020 – Although periodontitis is a widespread infectious disease affecting around 30% of the global population, there are currently no effective treatments available — yet.…


PerioTrap Pharmaceuticals ist Gesamtsieger des IQ Innovationspreis

Für die Kombination aus einem neuartigen Medikament und Therapieansatz zur Bekämpfung von Paradontitis auslösenden Keimen im Mundraum wurde die PerioTrap Pharmaceuticals GmbH aus Halle (Saale) mit…


Antimicrobial activity study has been published

After our mutual antimicrobial activity study has been published in April this year showing biofilm inhibition of our developed drug formulation, now the according paper detailing its optimized…